Anne Holck Storås begynte i november i 2019 i en 50% stilling som post doc ved Kreftregisteret. Hun er onkolog og jobber primært med urologisk kreft. Holck Storås jobber også 50% som overlege ved urologisk seksjon, Avdeling for Kreftbehandling, OUS i tillegg til jobben ved Kreftregisteret. Ved hjelp av registerdata skal hun se på helserelaterte utfall etter innføring av nye legemidler for metastatisk cancer prostata. Anne Holck Storås er utdannet lege fra universitetet i Oslo og spesialist i onkologi. Hun disputerte i 2017 med avhandlingen «Adverse effects after curative treatment for prostate cancer; an international perspective».
Health outcomes and prognostic factors after introduction of new anti-cancer drugs in patients with metastatic prostate cancer: A population-based study
1: Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, Ferrer F, Boladeras A, Zamora V, Fosså S, Storås AH, Sanda M, Serra-Sutton V, Ferrer M.
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis.
Cancer Treat Rev. 2018 May;66:23-44. doi: 10.1016/j.ctrv.2018.03.005. Epub 2018 Apr 3. Review. PubMed PMID: 29673922.
2: Fosså SD, Storås AH, Steinsvik EA, Myklebust TA, Eri LM, Loge JH, Dahl AA.
Psychometric testing of the Norwegian version of the Expanded Prostate Cancer
Index Composite 26-item version (EPIC-26). Scand J Urol. 2016 Aug;50(4):280-5. doi: 10.3109/21681805.2016.1163617. Epub 2016 Apr 6. PubMed PMID: 27049891.
3: Storås AH, Sanda MG, Boronat OG, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD.
Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients.
Clin Genitourin Cancer. 2016 Jun;14(3):e265-73. doi: 10.1016/j.clgc.2015.10.009. Epub 2015 Oct 26. PubMed PMID: 26778476.
4: Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD.
Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.
Clin Genitourin Cancer. 2014 Aug;12(4):e117-25. doi: 10.1016/j.clgc.2013.12.007. Epub 2014 Jan 3. PubMed PMID:24524968; PubMed Central PMCID: PMC5021779.
